, Volume 97, Issue 1, pp 118–122

Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex

  • Pamela A. Pierce
  • Stephen J. Peroutka
Original Investigations

DOI: 10.1007/BF00443425

Cite this article as:
Pierce, P.A. & Peroutka, S.J. Psychopharmacology (1989) 97: 118. doi:10.1007/BF00443425


The binding affinities of four hallucinogenic agents were analyzed at nine neurotransmitter binding sites in human cortex. d-Lysergic acid diethylamide (d-LSD), N,N-dimethyltryptamine (DMT), 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane (DOB) display highest affinity for the recently identified “DOB binding site” labeled by 77Br-R(-)DOB. The phenalkylamines, DOI and DOB, display subnanomolar affinity for the 77Br-R(-)DOB-labeled site, whereas the indolealkylamines, d-LSD and DMT, display nanomolar affinity for this site. d-LSD was the most potent of the four hallucinogens at six of the other eight sites analyzed in this study. All four hallucinogens also display high affinity for the 5-hydroxytryptamine2 (5-HT2) receptor subtype, with potencies ranging from 4 to 360 nM. Marked differences in relative affinities were observed between the indolealkylamines and the phenalkylamines at the 5-HT1A, 5-HT1D, and DOB binding sites. These rank-order differences in affinities are likely to account for the differing effects of these agents in various biochemical and physiological assays.

Key words

Hallucinogens Receptors Human cortex 

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Pamela A. Pierce
    • 1
  • Stephen J. Peroutka
    • 1
  1. 1.Department of Neurology and PharmacologyStanford University Medical CenterStanfordUSA